Overview

Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily

Status:
Completed

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

Summary

Bioequivalence trial in healthy adult subjects to determine the bioavailability of 3 different sustained release formulations of naproxen 660 mg relative to the established commercial Aleve 220 mg tablet.

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Treatments:

Naproxen